secwatch / observer
8-K filed April 3, 2026, 7:59 PM ET ticker ENTXW CIK 0001638097
other material confidence high sentiment positive materiality 0.75

Entera Bio raises $10M in private placement with BVF Partners to fund phase 3 osteoporosis study

Entera Bio Ltd.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Entera Bio Ltd. issued 7,827,789 units of unit to funds affiliated with BVF Partners LP for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).

Security
unit
Shares
7,827,789 units
Purchaser
funds affiliated with BVF Partners LP
Consideration
aggregate proceeds of approximately $10.0 (or $1.2775 per Unit)
Exact text from the filing
On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Entera Bio Ltd. entered into Purchase Agreement with funds affiliated with BVF Partners LP valued at approximately $10.0 (effective 2026-04-01).

Action
entry
Agreement
equity purchase
Counterparty
funds affiliated with BVF Partners LP
Value
approximately $10.0
Effective
2026-04-01
Exact text from the filing
On April 1, 2026, Entera Bio Ltd., a company organized under the laws of the State of Israel (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with funds affiliated with BVF Partners LP (collectively, the “ Purchaser ”), providing for the private placement (the “ Private Placement ”) to the Purchaser of an aggregate of 7,827,789 units (collectively, the “ Units ”), each Unit consisting of (i) one ordinary share, par value NIS 0.0000769 per share, of the Company (an “ Ordinary Share ”) (or, in lieu thereof, one pre-funded warrant to purchase one Ordinary Share (the “ Pre-Funded Warrants ”)) and (ii) one warrant to purchase one and a half Ordinary Shares (the “ Ordinary Share Warrant ”), for aggregate proceeds of approximately $10.0 (or $1.2775 per Unit).
View on SEC.gov

125 equity issuances filed in the last 30 days. Browse all equity issuances →

Entera Bio Ltd. filing history →

Source: SEC EDGAR
accession 0001178913-26-002001
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.